CurrentBlue Cross Blue Shield - OklahomaPolicy N/A

Prior Authorization Programs for Members on the Basic Drug List or Enhanced Drug List

Lists prescription drug categories and specific drugs that are subject to prior authorization under the payer's Basic Drug List or Enhanced Drug List; affects providers prescribing or requesting coverage for these drugs for Blue Cross Blue Shield - Oklahoma members.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyPrior Authorization Programs for Members on the Basic Drug List or Enhanced Drug List

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization requests for drugs listed on the Basic or Enhanced Drug List to avoid potential coverage denial.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

20+document chunks (partial list of categories/drugs)

20+distinct drug name mentions in this extract

Basic & Enhanceddrug list tiers referenced

VMAT2class repeatedly referenced

Coverage Criteria Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

The provided document extract does not contain explicit medical necessity criteria or clinical condition-based coverage rules. Instead, it presents an itemized listing of prescription drug products and categories that are included in the payer's prior authorization programs. There are no articulated eligibility conditions, diagnostic requirements, or stepwise clinical criteria in the cited material; coverage determinations for listed drugs are therefore driven by whether the product appears on the payer's Basic Drug List or Enhanced Drug List and the prior authorization process rather than by detailed medical necessity language in this extract.

The document functions as a catalog of drugs and category mappings and does not set out explicit exclusions. It enumerates products (for example, VMAT2 inhibitors and numerous specialty agents) and maps certain brand names into groupings or list tiers, but it does not specify clinical or coverage exclusions in the provided chunks. Providers should treat the listing as an index of products subject to prior authorization rather than a complete statement of covered versus excluded indications.

Provider Actions & Prior Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for drugs listed on the Basic Drug List or Enhanced Drug List. Providers must submit a prior authorization request for medications in these categories before dispensing to ensure coverage eligibility.

Prior authorization required for VMAT2 inhibitors (examples: Ingrezza / valbenazine, Austedo / deutetrabenazine, Voydeya).
Prior authorization required for specialty agents listed (examples: Wakix, Xolair, Xolremdi, Yorvipath, Zeposia, Zilbrysq, Zokinvy).
This mapping/listing reflects Basic/Enhanced Drug List categorizations and associated brand/generic pairings where provided.

Prior Authorization

Drug-List Prior Authorization Mappings

This section maps drug categories to specific brand and generic agents that require prior authorization. Use the mapping to identify which products fall under PA programs (example: VMAT2 Inhibitors mapped to Ingrezza, Austedo, Voydeya and their generic equivalents). The listing is not exhaustive and is subject to change.

VMAT2 Inhibitors (formerly Huntington's Disease / Tardive Dyskinesia) = Ingrezza (tetrabenazine/valbenazine variants), Austedo (deutetrabenazine/Austedo XR), Voydeya.
Specialty listed agents = Wakix, Xolair, Xolremdi, Yorvipath, Zeposia, Zilbrysq, Zokinvy.

Step Therapy

No Step Therapy Specified

There are no explicit step-therapy rules or required prior failures documented in the mapped chunks for these categories. Do not assume a required trial of alternative therapies unless a separate step-therapy policy or PA criterion states otherwise.

Documentation Required

Documentation / Submission

The source chunks do not provide explicit documentation or submission requirements beyond the need for prior authorization. Submit the standard PA request with clinical justification and supporting records as applicable; follow the payer's PA submission processes.

No specific forms, timelines, or documentation checklists were listed in these chunks.

Note

Contact for Questions

If you have questions about prior authorization requirements, mappings, or the listed drugs, call the number on the member's ID card for assistance.

Definitions and Drug Categories

Basic Drug List / Enhanced Drug List — tier definitions

DefinitionBasic Drug List / Enhanced Drug List: Drug list tiers referenced by the payer that determine which prescription drugs require prior authorization.

ScopeApplies to prescription drugs enumerated in the document; members obtaining listed products from either the Basic or Enhanced Drug List are subject to PA.

Provider actionPrior authorization requests must be submitted for drugs on these lists; failure to obtain PA may result in denial of coverage.

VMAT2 Inhibitors — class mapping

ClassVMAT2 Inhibitors — category label used in the document for agents formerly listed under Huntington's disease and tardive dyskinesia.

ContextDocument maps VMAT2 inhibitors to the Huntington's Disease / Tardive Dyskinesia category for PA purposes.

PA implicationVMAT2 inhibitors listed in this category are subject to prior authorization when obtained under the Basic or Enhanced Drug List.

VMAT2 Inhibitors — brand mappings

VoydeyaMapped repeatedly in the document to the VMAT2 Inhibitors category (formerly Huntington's disease/tardive dyskinesia).

IngrezzaListed as a VMAT2 inhibitor (Ingrezza) and mapped to the VMAT2 Inhibitors category for PA.

Austedo (Austedo XR)Listed as Austedo / Austedo XR and mapped to the VMAT2 Inhibitors category for PA.

Step Therapy / Tier Mappings

Group	Examples / Notes
1
Entries labeled '1' in the document indicate preferred or primary groupings within a category (example: multiple biologic immunomodulators are listed as '1' in chunk 7).
2
Entries labeled '2' indicate alternate or secondary groupings within a category (example: alternate biologic products listed as '2' in chunk 7).

Class / Policy Mapping	Prior Authorization Implication
VMAT2 inhibitors (formerly listed under Huntington's disease / tardive dyskinesia)
Document groups VMAT2 inhibitors as a mapped class subject to prior authorization on the Basic or Enhanced Drug List; no numeric step order is specified in the source chunks.

Brand / Product	Class Mapping / PA Status
Austedo (Austedo XR)
Mapped to VMAT2 inhibitors class and listed as subject to prior authorization under the Basic/Enhanced Drug List.
Ingrezza
Mapped to VMAT2 inhibitors class and listed as subject to prior authorization under the Basic/Enhanced Drug List.
Xenazine (tetrabenazine)
Mapped to VMAT2 inhibitors class and listed as subject to prior authorization under the Basic/Enhanced Drug List.
Voydeya
Mapped to VMAT2 inhibitors class and listed as subject to prior authorization under the Basic/Enhanced Drug List.